Chai Discovery scores Big Pharma deal after OpenAI exodus

Remember when everyone was watching OpenAI employees scatter to the winds? Well, some of them landed at Chai Discovery, and now they're making waves in AI drug development with a fresh Eli Lilly partnership.

Here's what caught my attention about Chai Discovery. They're not just another AI startup promising to "revolutionize healthcare" (ugh, I hate that phrase). Instead, they're focusing on something pretty specific: using AI to predict how proteins fold and interact. Sounds nerdy, but this is exactly the kind of problem where AI actually shines. Proteins are ridiculously complex, and figuring out their shapes helps design better drugs.

The Eli Lilly deal is a big validator. When a pharma giant with over $30 billion in revenue decides to partner with you, it means they've seen something worth betting on. And Chai's got some serious Silicon Valley muscle behind them too. We're talking about VCs who usually chase the next social media app suddenly getting excited about molecular biology.

What I find interesting is the timing. AI drug discovery has been bubbling for years, but 2026 feels like the year it's actually delivering results. Companies like Chai aren't just running simulations anymore. They're getting real pharmaceutical partners who want to turn these AI predictions into actual medicines.

The OpenAI connection adds another layer to the story. These folks could've gone anywhere after leaving, probably started another chatbot company or something. But they chose drug discovery. That tells me they see massive potential here, beyond just the hype cycle we've all gotten used to with AI announcements.